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Background: The study estimates mortality dynamics (event-specific hazard rates over a follow-up time interval) for
uveal melanoma.
Methods: Three thousands six hundred seventy two patients undergoing radical or conservative treatment for
unilateral uveal melanoma, whose yearly follow-up data were reported in three published datasets, were analysed.
Mortality dynamics was studied by estimating with the life-table method the discrete hazard rate for death.
Smoothed curves were obtained by a Kernel-like smoothing procedure and a piecewise exponential regression
model. The ratio deaths/patients at risk per year was the main outcome measure.
Results: The three explored hazard rate curves display a common bimodal pattern, with a sudden increase peaking
at about three years, followed by reduction until the sixth-seventh year and a second surge peaking at about nine
years after treatment.
Conclusions: The bimodal pattern of mortality indicates that uveal melanoma metastatic development cannot be
explained by a continuous growth model. Similar metastasis dynamics have been reported for other tumours,
including early breast cancer, for which it supported a paradigm shift to an interrupted growth model, the
implications of which are episodes of ‘tumour dormancy’. We propose that the concepts of tumour homeostasis,
tumour dormancy and enhancement of metastasis growth related to primary tumour removal, convincingly
explaining the clinical behaviour of breast cancer, may be used for uveal melanoma as well. To confirm this
proposition, a careful analysis of uveal melanoma metastasis dynamics is strongly warranted.Background
Thirty four years ago Lorenz E Zimmerman, Ian WMcLean,
and Walter D Foster published the landmark article “Does
enucleation of the eye containing a malignant melanoma
prevent or accelerate the dissemination of tumour cells?”
[1]. In that article the authors put forward a hypothesis
casting doubts on the benefit of enucleation that was the
prevailing management of choroidal melanoma at that
time. Their work stimulated the development of alter-
native therapies including various forms of radiotherapy
and tumour resection, resulting in successive wide diffu-
sion of “conservative” treatments [2]. Their hypothesis
was primarily based on the mortality pattern, estimated
from an historical series, which apparently peaked 2–3
years after enucleation and stabilised by the seventh year* Correspondence: demicheliromano@istitutotumori.mi.it
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reproduction in any medium, provided the orof follow-up. The clinical, epidemiological, statistical, and
experimental evidence developed over the elapsed 34 years
since the publication of the hypothesis confirms the
phenomenon of transient rise in post-therapeutic mor-
tality. Although most ophthalmologists do not presently
attribute this fact to the procedure of enucleation, and be-
lieve that it can be explained on the basis of early metasta-
sis, questions implied by the Zimmerman-McLean-Foster
hypothesis are still valid [3].
The sudden emergence of metastatic disease in the early
years following primary tumour removal is not limited to
uveal melanoma. Similar recurrence patterns have been
reported for early breast cancer [4], non-small-cell lung
cancer (NSCLC) [5] and head and neck cancer [6], for
which an additional later recurrence peak is also detect-
able. For breast cancer, this result confirmed the previous
evidence that continuous tumour growth is irreconcilable
with clinical findings [7] and supported a paradigm shift
to an interrupted growth model, the implications of whichral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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paradigm, primary tumour removal, usually considered as
intrinsically beneficial, can perturb metastatic homeostasis
and, for some patients, results in the acceleration of meta-
static development [8]. The occurrence of a second mor-
tality peak for choroidal melanoma was suggested from
RBS Packard [9] more than 30 years ago. To our know-
ledge, however, the issue was not further addressed by
other investigators.
As data of uveal melanoma annual mortality are avail-
able in a few published reports, we performed an ana-
lysis of the hazard rate for mortality with the same
technique adopted to estimate breast cancer event dy-
namics (event-specific hazard rates over a follow-up time
interval). Such an analysis, aimed at exploring analogies
between the clinical courses of these different neoplasias
possibly relying on similar metastasis behaviours, is the
object of present report.
Methods
A first set of data on the follow-up of patients undergo-
ing enucleation for uveal melanoma were directly drawn
from Table 1 of the report from Mc Lean IW et al [10].
The table encloses the annual number of patients either
died from melanoma metastasis or censored, among 2105
patients recorded in the Registry of Ophthalmic Pathology
of the Washington Hospital Centre, mostly between 1940
and 1960. A second dataset, from the Royal Ophthalmic
Hospital and Royal Eye Hospital of London on 250 patients
treated for uveal melanoma between 1925 and 1939, was
found in Table four of the paper from Benjamin B et al.
[11]. The table encloses annual numbers of deaths from
melanoma metastasis and average numbers of patients at
risk. The third dataset originates from the randomized
multicentre clinical trial of brachytherapy versus enucle-
ation conducted by the Collaborative Ocular MelanomaTable 1 Patient characteristics of the studied uveal
melanoma series
Mc Lean series Benjamin series COMS series
Number of patients 2055 250 1317
Sex (Males/females) Not reported 116/134 665/652
Mean age (Years) 55 54 60
Tumour size1 (%)
Small 27 35
Medium 43 Not reported 57
Large 30 8
Cell type (%)
Spindle cell 45 64 Not reported
Mixed cell2 55 36
1–Small: ≤ 10 mm; medium: 11–15 mm; large: >15 mm.
2–Mixed cell: includes the mixed, fascicular and epithelioid type of the
Callender classification.Study (COMS) Group on 1317 patients with medium-sized
choroidal melanoma, enrolled from 1986 to 2003, and was
obtained from Figure 1 of the COMS report N° 28 [12].
The dataset provides the number of deaths with histo-
pathologically confirmed melanoma metastasis and the
number of censored events. Data from the COMS clinical
trial of enucleation versus pre-enucleation radiation ther-
apy for large tumours was not considered suitable for the
analysis due to the insufficient follow-up of the available
dataset (COMS report N° 24 [13]). Patient and tumour
characteristics are available in the reported papers.
Mortality dynamics was studied by estimating with the
life-table method the discrete hazard rate for death,
i.e., the conditional probability of dying in a time interval,
given that the patient was alive at the beginning of the
interval. A discretization of the time axis in one year units
was applied. Therefore, all hazard rate levels were mea-
sured as ‘events/patients at risk per year’. Since the hazard
rate estimates display some instability due to random vari-
ation, a Kernel-like smoothing procedure was adopted
and the smoothed curve was graphically represented to
make it easier for the reader to perceive the underlying
pattern [14]. This method, which is akin to a moving aver-
age, estimates the events/exposure rate at each time point
by a local weighted mean of the observations.
In addition to the Kernel smoothing approach with
discrete hazards, a flexible parametric approach based
on the piecewise exponential model was also adopted in
order to obtain smoothed hazard estimates [15]. Natural
cubic splines, i.e., with linearity constraints on the tails,
were used with knots placed equidistantly within the re-
spective year ranges. The number of knots, correspond-
ing to a number of basis functions between 3 and 8, was
chosen by minimizing the Akaike Information Criterion
(AIC). AIC estimates the relative distance between the
fitted and the true model, and increases when unneces-
sary flexibility is added to the model. This criterion is suit-
able for model selection even when fitted models are not
nested, as is the case when splines knots locations change
according to their number [16]. The 95% point-wise confi-
dence intervals were based on the log transformation. For
a comparison with a regularized (e.g., smoothing) regres-
sion approach, P-splines [17] were also used, where a
maximum number of knots is chosen from the beginning,
and, to avoid overfitting, a term penalizing the roughness
of the estimator is introduced. The trade-off between fit
to observed data and curve smoothness is regulated by a
penalty parameter.
Results
A few patient and tumour characteristics are reported in
Table 1. The hazard rate pattern for uveal melanoma mor-
tality for the McLean and Benjamin series is reported in
Figure 1. The two explored hazard rate curves display a
Figure 1 Cause-specific hazard rate estimates for mortality in patients undergoing eye enucleation for uveal melanoma. Blue line: data
on 2105 patients from the McLean series. Red line: data on 250 patients from Benjamin series. Time-origin is at surgery. (Upper panel) Smoothed
curves are obtained by a Kernel-like smoothing procedure. Standard deviation estimates for single points are also reported. (Lower panel) Hazard
rates obtained by the piecewise exponential regression model. Vertical lines represent 95% point-wise confidence intervals.
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at about three years, followed by less rapid reduction
until the sixth-seventh year and a second surge peak-
ing at about nine years after enucleation. This pattern
is well detectable in the Benjamin series, in spite of
the less extended follow-up. Of note, this older series
displays a lower hazard level in comparison with the
more recent McLean series, yet maintaining the same
overall pattern.
The COMS randomized study confirmed that there is
no survival difference between patients whose tumours
are treated with radical treatment and those treated with
conservative treatment. Consequently, the two series
were merged and jointly analysed, after confirmation
that the recurrence dynamics for patients undergoing
brachytherapy is similar to the corresponding pattern forenucleated patients (data not shown) (Figure 2). The re-
currence dynamics for these patients once again displays
the bimodal pattern, although with minor differences in
the peak timing when compared with the older series,
an occurrence that may be compatible with different
data collection accuracies.
Discussion
Our analysis provides evidence that the mortality dy-
namics for patients undergoing enucleation for uveal
melanoma displays a bimodal pattern (Figure 1). More-
over, similar mortality dynamics was detected for patients
with choroidal melanoma treated with either surgery or
radiation therapy (Figure 2). It should be noted that the
characteristics of the two series display dissimilarities in
the frequency of a few prognostic parameters (Table 1),
Figure 2 Cause-specific hazard rate estimates for mortality in 1317 patients from the COMS series, undergoing either I125 brachytherapy
or enucleation for unilateral choroidal melanoma. Time-origin is at surgery. (Upper panel) Smoothed curves are obtained by a Kernel-like
smoothing procedure. Standard deviation estimates for single points are also reported. (Lower panel) Hazard rates obtained by the piecewise
exponential regression model. Vertical lines represent 95% point-wise confidence intervals.
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trait of bearing a tumour that could be dealt with enucle-
ation. The occurrence that a bimodal pattern was detected
in datasets from different institutions, regarding patients
with different characteristics treated during different time
spans and with different modalities strongly supports the
validity of the result that emerges in spite of possible con-
founding factors. Of note, moreover, if the mortality data
reported by RBS Packard [9] are analysed with the same
technique adopted by us, the same bimodal mortality pat-
tern evidently emerges (Figure 3).
Similar pattern was formerly detected for early breast
cancer [4] and, more recently, for NSCLC [5] and head
and neck cancer [6]. In particular, this finding raises the
possibility that major analogies may exist between uveal
melanoma and early breast cancer metastasis biology, al-
though the latter was inferred from recurrence dynamics
rather than from mortality. It is very reasonable, how-
ever, to assume that uveal melanoma recurrence dynam-
ics have a bimodal pattern as well, although with earlier
peak timing in comparison with mortality. Indeed about
90% of recurring uveal melanoma patients display meta-
static liver involvement with median survival time of lessthan 6 months from metastasis detection, largely due to
the lack of effective treatments for metastatic disease
[18]. The assumption is also strengthened by the finding
that breast cancer mortality dynamics still maintains bi-
modal pattern, in spite of the fact that survival following
recurrence is much more prolonged and displays high
inter-patient variability [19]. Uveal melanoma and early
breast cancer, moreover, display a few other remarkable
clinical similarities, supporting analogy in metastasis biol-
ogy, at least after surgical treatment: (i) uncommon obser-
vation of metastases at diagnosis; (ii) complete primary
tumour removal; (iii) early recurrence after surgery in a
substantial number of patients; (iv) prolonged risk of recur-
rence, with late metastasis emergence even after decades.
Additionally, the occurrence that in patients with choroidal
melanoma similar mortality dynamics is detectable after
surgery or radiotherapy suggests that in ocular melanoma
similar metastatic development biology may occur follow-
ing the two different primary tumour treatments.
On the basis of such analogies, we may hypothesize that
the concepts of tumour homeostasis, tumour dormancy
and surgery related enhancement of metastasis growth,
convincingly explaining the clinical behaviour of breast
Figure 3 Cause-specific hazard rate estimates for mortality in 578 patients treated at the Moorfields Eye Hospital between 1949 and
1972 for Choroid melanoma. Time-origin is at surgery. (Upper panel) Smoothed curves are obtained by a Kernel-like smoothing procedure.
Standard deviation estimates for single points are also reported. (Lower panel) Hazard rates obtained by the piecewise exponential regression
model. Vertical lines represent 95% point-wise confidence intervals.
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cording to this biology, following tumour cell shedding
from the primary, the development of metastases includes
sequential passage through a few phases: (a) single mostly
non-dividing tumour cells (cellular dormancy), (b) non-
angiogenic micro-metastases (and angiogenic ones in the
presence of anti-angiogenic factors) that cannot grow
more than the size of avascular foci (micrometastatic dor-
mancy) and (c) vascularised growing metastases doomed
to reach the clinical level. This orderly process is con-
trolled by the primary tumour that can exert restraints on
the transition between dormancy phases by not yet well
elucidated mechanisms, thus retarding or inhibiting
metastasis development. Surgical removal (and brachy-
therapy for choroidal melanoma) of primary tumour may,
therefore, disrupt such a tumour homeostasis [20], with
sudden synchronization and acceleration of the metastatic
process, at least for some patients, and originate the firstmortality peak. Residual single dormant cells and avascular
micrometastases, the amount of which cannot increase
further due primary tumour removal, will follow an unper-
turbed course resulting in the late mortality peak. Details
of the process supporting the acceleration of metastasis
are not yet well understood. Both the treatment trauma
per se (activation of the healing programme) and the pri-
mary tumour removal (disruption of homeostatic equilib-
rium) are strongly suspected to be relevant. Angiogenesis
induction by shifted balance between enhancing and inhi-
biting factors may be an important, but not exclusive, mo-
lecular mechanism for dormancy interruption, while, on
the basis of present results, current treatment modalities
of primary tumour apparently seem to play a minor role.
A comment is needed on the question of why Zimmerman
and colleagues did not report a bimodal pattern in their
analysis [1]. It should be noted that they obtained a least-
square fit to the observed data by a mathematical model
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tinuous tumour growth. If one looks at the experimental
points in their Figure 3, the occurrence of a second surge
of annual death rate at the 9th year is quite evident. A dif-
ferent more flexible smoothing approach would have prob-
ably called their attention on the late structure of the
mortality pattern. Similar considerations may be put for-
ward for the mortality analysis carried out in another study
on a dataset partially overlapped to the McLean series [21].
Zimmerman, McLean, and Foster attributed the
phenomenon they identified to the modalities of the
surgical manoeuvre and hoped that, by paying atten-
tion to the details of enucleation and by irradiating the
eye before this procedure, one might improve the progno-
sis of patients with uveal melanoma. Yet, all subsequent
research efforts failed to provide evidence of prognosis im-
provement by technique refinements of the primary treat-
ment. According to our proposed paradigm, this failure is
perfectly explainable, since the reason for the early rise of
recurrence and mortality after treatment of the primary is
related to the treatment itself, not to technical details by
which it is carried out.
For early breast cancer, peak timing is rather constant
for all studied patient subsets while risk levels are greatly
influenced by tumour and host traits [8]. The double
peaked risk profile of a given patient is seemingly deter-
mined by a unique mix of tumour-host factors control-
ling the ability of tumour cells to progress throughout
successive dormant states. Uveal melanoma might display
similar behaviour: some factors may result from the
tumour originating cell (e.g., gene profile or chromosomal
anomalies such as chromosome 3 deletion), or by tumour
traits (e.g., location or size) while others may result from
host traits (e.g., sex, age) [22]. This occurrence is somehow
anticipated by the report from RBS Packard [9] where
bimodality is detectable in all analysed subsets (by dur-
ation of history, position and size of the tumour, cell type
and scleral extension), in spite of the relatively naïve
analysis. Further studies on this subject are needed. In
particular, the fact that microarray-based gene expression
profiling is able of discriminating two molecular prog-
nostic classes (aggressive vs less aggressive) [23] should be
carefully examined. This point recalls a similar question
involving breast cancer prognosis, which may be related
to oestrogen receptor (ER) status (ER positive vs ER nega-
tive), Her2 expression (Her2 positive vs Her2 negative) or
to a combined classifier (triple negative vs others). Since
the bimodal recurrence dynamics for breast cancer pa-
tients was detected in all subsets [24,25], without sup-
porting the evidence for a “two population” hypothesis, in
the absence of a (required) direct analysis of data we are
inclined to think that for uveal melanoma also these prog-
nostic classes may impact on peak height, not on peak
position.Conclusions
Our analysis reveals that the mortality dynamics for pa-
tients undergoing enucleation or brachytherapy for uveal
melanoma displays a bimodal pattern. Although the oc-
currence of a second mortality peak was suggested more
than 30 years ago, the issue was not further addressed by
other investigators and no reasonable explanation was put
forward. Our investigation, which confirms that this pat-
tern is detectable in datasets from different institutions
and regarding patients treated during different time spans
and with different modalities, strongly supports the valid-
ity of the result.
We suggest that the concepts of tumour homeostasis,
tumour dormancy and surgery related enhancement of
metastasis growth, convincingly explaining the clinical
behaviour of breast cancer, may be used for uveal melan-
oma as well.
Results of the study have potential implications on treat-
ment approaches and surveillance, which might indeed
benefit from time-related recurrence rate modifications.
We acknowledge, however, that confirmation of the pro-
posed new paradigm for uveal melanoma needs careful
analyses of the recurrence dynamics by patient and tumour
traits. Such investigations are strongly warranted.
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